| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/16/2009 | US20090098096 Agent for correcting stress-inducing neuro-mediator, neuro-endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 04/16/2009 | US20090098086 Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| 04/16/2009 | US20090098085 Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| 04/16/2009 | US20090098084 Parp inhibitor compounds, compositions and methods of use |
| 04/16/2009 | US20090098082 substiuted organopolysiloxanes and use thereof |
| 04/16/2009 | US20090098081 System for providing a method for applying a skin sealant having a phase change visual indicating component |
| 04/16/2009 | US20090098069 Transdermal, alcohol-free, pharmaceutical compositions |
| 04/16/2009 | US20090098067 Foamable sanitizing compositions |
| 04/16/2009 | US20090098066 Substituted bicyclo [2.2.2] oct/5-ene compounds and their use as cooling agents |
| 04/16/2009 | US20090098065 Composition and methods for the treatment of skin disorders |
| 04/16/2009 | US20090098063 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| 04/16/2009 | US20090098061 Solution for tissue adhesion prevention and method for tissue adhesion prevention |
| 04/16/2009 | DE202009000862U1 Dosiereinheit und Zusammensetzung zur Behandlung von entzündlichen Erkrankungen des Mund- und Rachenraums Dosing and composition for the treatment of inflammatory diseases of the mouth and throat |
| 04/16/2009 | DE102008051140A1 Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur Begrenzung/Minderung des Risikos einer Tiefen-Venen-Thrombose in Einheit mit einer oralen Kontrazeption Process for the preparation of a pharmaceutical preparation einphasischen to limit / reduce the risk of deep vein thrombosis in unity with oral contraception |
| 04/16/2009 | DE102008009752A1 Beverage for improving the state of health, contains chili pepper juice and grape fruit juice that are mixed to the beverage without alcohol |
| 04/16/2009 | DE102007049157A1 New substituted 2,3-dihydro-(1,2,3)triazol-4-one compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, inflammatory disease and anemia |
| 04/16/2009 | DE102007048705A1 Amorphe Formulierung Amorphous formulation |
| 04/16/2009 | DE102007048447A1 New substituted dihydropyrazole-3-thione compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, wound healing and anemia |
| 04/16/2009 | DE102007048335A1 Use of I-f inhibitor for the preparation of a medicament to treat erectile dysfunction |
| 04/16/2009 | CA2740200A1 Methods and compositions for treating dermatological diseases and conditions |
| 04/16/2009 | CA2739719A1 Laminins, derivatives, and compositions including same and method for their therapeutic use |
| 04/16/2009 | CA2709224A1 Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells |
| 04/16/2009 | CA2704009A1 Preparation, use of preparation for treatment, and method of treatment of intestinal infection |
| 04/16/2009 | CA2702470A1 Functional lipid constructs |
| 04/16/2009 | CA2702366A1 Compositions affecting hyaluronic acid mediated activity |
| 04/16/2009 | CA2702356A1 Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake |
| 04/16/2009 | CA2702339A1 Anti-glycation methods and compositions |
| 04/16/2009 | CA2702265A1 Novel seh inhibitors and their use |
| 04/16/2009 | CA2702257A1 Broad spectrum beta-lactamase inhibitors |
| 04/16/2009 | CA2702225A1 Diphenyl substituted cycloalkanes |
| 04/16/2009 | CA2702221A1 Methods and kits for the treatment of diverticular conditions |
| 04/16/2009 | CA2702211A1 Extrudable and extruded compositions for delivery of bioactive agents, method of making same and method of using same |
| 04/16/2009 | CA2702181A1 Benzothiazoles as ghrelin receptor modulators |
| 04/16/2009 | CA2702171A1 Amide compound |
| 04/16/2009 | CA2702152A1 Process for the manufacture of a pharmaceutical product |
| 04/16/2009 | CA2702132A1 Spiropyrrolidines and their use against hcv and hiv infection |
| 04/16/2009 | CA2702111A1 Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders |
| 04/16/2009 | CA2702103A1 Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| 04/16/2009 | CA2702101A1 Aryl amides useful as inhibitors of voltage-gated sodium channels |
| 04/16/2009 | CA2702082A1 Aqueous ophthalmic formulations |
| 04/16/2009 | CA2702045A1 Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| 04/16/2009 | CA2702023A1 Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient |
| 04/16/2009 | CA2702008A1 Inhibitors of protein kinases |
| 04/16/2009 | CA2701946A1 Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| 04/16/2009 | CA2701932A1 Chiral cis-imidazolines |
| 04/16/2009 | CA2701904A1 Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
| 04/16/2009 | CA2701880A1 Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient |
| 04/16/2009 | CA2701868A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | CA2701865A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | CA2701853A1 Organic compounds |
| 04/16/2009 | CA2701839A1 N- (pyrazole-3-yl) -benzamide derivatives as glucokinase activators |
| 04/16/2009 | CA2701806A1 Pyridine derivatives useful as glucokinase activators |
| 04/16/2009 | CA2701766A1 Amides useful as inhibitors of voltage-gated sodium channels |
| 04/16/2009 | CA2701764A1 Photodynamic therapy process and photosensitizer compositions |
| 04/16/2009 | CA2701695A1 Pharmaceutical formulation of valsartan |
| 04/16/2009 | CA2701626A1 Compounds from myrothecium sp. for inhibiting the growth of cancer cells |
| 04/16/2009 | CA2701568A1 Imidazole derivatives |
| 04/16/2009 | CA2701525A1 Thiazole derivatives |
| 04/16/2009 | CA2701519A1 Piperidine and piperazine derivatives |
| 04/16/2009 | CA2701385A1 Composition 064 |
| 04/16/2009 | CA2701189A1 Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| 04/16/2009 | CA2701161A1 Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation |
| 04/16/2009 | CA2701057A1 Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors |
| 04/16/2009 | CA2700893A1 Substituted tetrazole compounds and uses thereof |
| 04/16/2009 | CA2700880A1 Antimalarial compounds with flexible side-chains |
| 04/16/2009 | CA2700824A1 Heterocyclic compounds as crth2 receptor antagonists |
| 04/16/2009 | CA2700803A1 Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes |
| 04/16/2009 | CA2700795A1 Isoxazole compound for the treatment of cancer |
| 04/16/2009 | CA2700783A1 Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| 04/16/2009 | CA2700759A1 Benzocycloheptene derivatives as estrogens having selective activity |
| 04/16/2009 | CA2700049A1 Novel compounds as cannabinoid receptor ligands |
| 04/16/2009 | CA2699788A1 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| 04/16/2009 | CA2699674A1 5-ht7 receptor antagonists |
| 04/16/2009 | CA2699504A1 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
| 04/16/2009 | CA2699090A1 Combination therapy with antibody-drug conjugates |
| 04/16/2009 | CA2698326A1 Antibody targeting osteoclast-related protein siglec-15 |
| 04/16/2009 | CA2697458A1 A novel non-aqueous topical solution of diclofenac and process for preparing the same |
| 04/16/2009 | CA2696424A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 |
| 04/16/2009 | CA2696423A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2 |
| 04/16/2009 | CA2683628A1 Method of treating vitamin d insufficiency and deficiency |
| 04/15/2009 | EP2048235A2 Synthetic Mammalian Alpha-N-Acetylglucosaminidase and Genetic Sequences Encoding Same |
| 04/15/2009 | EP2048153A1 Substituted spiroketal derivative and use thereof as drug for treating diabetes |
| 04/15/2009 | EP2048152A1 Fused ring spiroketal derivative and use thereof as drug for treating diabetes |
| 04/15/2009 | EP2048150A1 Benzyl phenyl glucopyranoside derivative |
| 04/15/2009 | EP2048145A1 Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof |
| 04/15/2009 | EP2048143A1 Prodrug of cinnamide compound |
| 04/15/2009 | EP2048142A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| 04/15/2009 | EP2048141A1 Optical pure dihydropyrimidine compounds, their uses in the manufacture of a medicamnent for the treatment or the prevention of virosis diseases |
| 04/15/2009 | EP2048138A1 Salt or solvate of 5-methyl-2-(piperazin-1-yl)benzenesulfonic acid |
| 04/15/2009 | EP2048137A1 Benzamide derivatives and their use as glucokinase activating agents. |
| 04/15/2009 | EP2048135A1 Use of monohydroxycarbamazepine in the treatment of neuropathic pain and related disorders |
| 04/15/2009 | EP2048134A1 Meptazinol biligand derivatives and/or their salts, preparation method and uses thereof |
| 04/15/2009 | EP2048133A1 Nicotinamide n-oxide derivatives as vanilloid-1 receptor modulators |
| 04/15/2009 | EP2048132A1 Tetrahydro-naphthalene and urea derivatives |
| 04/15/2009 | EP2048126A1 Benzocycloheptane derivatives as selectively active oestrogens |
| 04/15/2009 | EP2047864A1 Use of rpn2 gene expression inhibitor |
| 04/15/2009 | EP2047858A1 Combination products for treating cancer |
| 04/15/2009 | EP2047856A1 Agent for preventing infection |
| 04/15/2009 | EP2047855A1 Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants) |
| 04/15/2009 | EP2047854A1 Pharmaceutical formulations containing ferrous bisglycinate chelate in combination with sweeteners (acesulfam K, sucralose, sorbitol) for improved palatability |